Pharmacogenomics Archives - InnoHEALTH magazine

From genome to phenome: The impact of genetic insights on health outcomes

InnoHEALTH magazine digital team — Mon, 31 Jul 2023 05:00:03 +0000

Genomics and phenomics are two interconnected fields that play a crucial role in understanding the relationship between our genes and their expression in various traits and characteristics. Genomics focuses on the study of an organism’s entire set of genes, known as the genome, while phenomics explores the observable traits and characteristics, known as the phenotype, resulting from the interaction between genes and the environment. Together, genomics and phenomics provide a comprehensive view of how our genes influence our health, development, and overall well-being.

The Genome: The Blueprint of Life

The genome can be thought of as the blueprint of life. It encompasses all the genetic material present in an organism, including the DNA sequences that make up genes. Genes are responsible for encoding proteins, the building blocks of life, which carry out essential functions in our bodies. The genome also includes non-coding DNA regions that regulate gene expression and contribute to various aspects of our biology.

The human genome consists of approximately 3 billion base pairs, which are arranged in a unique sequence. This sequence determines the genetic code that provides instructions for the formation and functioning of every cell in our bodies. The genome is organised into chromosomes, with each cell typically containing 23 pairs of chromosomes, including the sex chromosomes.

Advancements in genomics technologies, such as DNA sequencing, have revolutionised our ability to decipher and analyse the genome. This has led to groundbreaking discoveries about the genetic basis of diseases, the identification of genetic variations associated with traits and conditions, and the development of personalised medicine approaches.

The Phenome: An Expression of Our Genes

The phenome encompasses all the observable traits, characteristics, and behaviors of an organism. It is the result of the complex interplay between genetic factors and environmental influences. Phenotypes can vary widely among individuals, even if they share similar genetic backgrounds, due to the influence of external factors such as lifestyle, diet, and exposure to environmental factors.

Phenotypes can include physical attributes (e.g., height, eye colour), physiological traits (e.g., blood pressure, cholesterol levels), and disease susceptibility or resistance. They can also encompass behavioural traits, cognitive abilities, and responses to medications. By studying phenotypes, researchers gain valuable insights into the interplay between genes and the environment and how they contribute to variations in health outcomes and disease risk.

The Genome-Phenome Interaction: A Complex Interplay

The relationship between the genome and the phenome is a complex interplay influenced by multiple factors. While our genes provide the foundation for our biological makeup, they do not act alone in determining our phenotypic traits. Environmental factors, such as diet, lifestyle, exposure to toxins, and social determinants of health, also play significant roles in shaping our phenotypes.

The genome-phenome interaction involves a dynamic process influenced by gene expression, epigenetics (the study of heritable changes in gene activity without changes to the underlying DNA sequence), and gene-environment interactions. Gene expression refers to the activation or deactivation of specific genes in response to various internal and external stimuli.

Understanding the genome-phenome interaction is essential for unravelling the complexities of human health and disease. It enables researchers to identify genetic variations associated with specific phenotypes, discover underlying molecular mechanisms, develop targeted therapies, and improve disease prevention and management strategies. Additionally, it provides insights into how environmental factors can modify gene expression and impact health outcomes.

In summary, genomics and phenomics provide a comprehensive understanding of the complex interplay between our genes and the observable traits and characteristics they influence. By studying the genome-phenome interaction, researchers are uncovering valuable insights that have far-reaching implications for personalised medicine, disease prevention, and improving overall health outcomes.

From Genes to Disease: Understanding the Connection

Understanding the connection between genes and disease is a crucial area of research that has the potential to revolutionise our approach to healthcare. Genes play a significant role in determining our susceptibility to various diseases, and unravelling this connection can provide valuable insights into disease prevention, early diagnosis, and targeted treatments.

Genes are segments of DNA that contain the instructions for building and maintaining our bodies. They carry the genetic information that is passed down from our parents and are responsible for the traits and characteristics we inherit. However, genes can also harbour mutations or variations that can impact our health.

Genetic research has identified specific genes and genetic variants that are associated with various diseases. Some diseases, known as monogenic disorders, are caused by mutations in a single gene. Examples include cystic fibrosis, sickle cell anaemia, and Huntington’s disease. Understanding the specific gene mutations that underlie these disorders is crucial for diagnosis and targeted interventions.

In addition to monogenic disorders, genes also play a role in complex diseases such as diabetes, cardiovascular disease, cancer, and neurodegenerative disorders. These diseases result from a combination of genetic variations, environmental factors, and lifestyle choices. Identifying the genetic risk factors associated with complex diseases can help in assessing an individual’s susceptibility and implementing preventive strategies.

The Impact of Genomic Information on Health Outcomes

The availability of genomic information has profound implications for health outcomes. It enables healthcare providers to identify individuals who are at higher risk for developing certain diseases, allowing for targeted screening and early intervention. For example, individuals with a high genetic risk for breast cancer may undergo more frequent screenings or consider risk-reducing strategies such as preventive surgeries or targeted therapies.

Genomic information also plays a crucial role in precision medicine, where treatments are tailored to an individual’s genetic profile. Pharmacogenomics, a branch of precision medicine, examines how genetic variations influence an individual’s response to medications. This information helps guide medication selection and dosing, improving treatment efficacy and reducing adverse drug reactions.

Furthermore, genomic information contributes to our understanding of disease biology and the development of novel therapies. By identifying specific genes or molecular pathways involved in disease progression, researchers can develop targeted drugs or gene therapies that address the underlying causes of the disease, potentially leading to more effective treatments.

The Phenotypic Impact: How Genes Shape Health

Phenotype refers to the observable characteristics of an individual, such as physical traits, behaviors, and disease manifestations. Genes play a fundamental role in shaping our phenotype. However, it is important to note that while genes provide the blueprint, other factors such as environmental influences and lifestyle choices can modify or interact with genetic predispositions.

Understanding the phenotypic impact of genes is a complex task. Genetic variations can have varying degrees of influence on an individual’s health outcomes. Some variations may have a strong causal relationship with a disease, while others may increase susceptibility or modify the disease course.

Additionally, gene-gene interactions and gene-environment interactions contribute to the phenotypic complexity. Two individuals with the same genetic variant may have different disease outcomes depending on their environmental exposures or other genetic factors.

Advances in technologies like high-throughput sequencing and bioinformatics are enhancing our ability to uncover these complex gene-environment interactions and decipher the phenotypic impact of genetic variations. This knowledge is crucial for understanding disease mechanisms, predicting disease risk, and developing personalised interventions that target the specific genetic and environmental factors involved.

Genome to Phenome: The Journey of Precision Medicine

Precision medicine has revolutionised the healthcare landscape by recognizing the unique genetic makeup of individuals and tailoring treatments accordingly. At the core of precision medicine is the concept of transitioning from the genome, which represents an individual’s complete set of genetic information, to the phenome, which encompasses the observable traits and characteristics influenced by those genes. This journey from the genome to the phenome has the potential to unlock valuable insights and improve health outcomes in remarkable ways.

Genetic Testing and Its Role in Improving Health Outcomes

Genetic testing plays a crucial role in the journey from the genome to the phenome. It involves the analysis of an individual’s genetic material to identify variations or mutations that may be associated with specific diseases or conditions. By undergoing genetic testing, individuals gain insight into their genetic predispositions, allowing for early detection, prevention, and personalised treatment strategies. Genetic testing helps healthcare providers make informed decisions, prescribe appropriate medications, and monitor potential risks, resulting in improved health outcomes.

Genetic testing encompasses various techniques, including whole genome sequencing, targeted gene panel testing, and specific gene variant analysis. The choice of genetic testing method depends on the clinical context and the specific questions being addressed. As technology advances, genetic testing is becoming more accessible, cost-effective, and informative, empowering individuals to take an active role in managing their health.

The Use of Genomic Information in Clinical Practice

Integrating genomic information into clinical practice is a critical step in the journey from the genome to the phenome. By considering an individual’s genomic profile alongside their medical history, lifestyle factors, and environmental influences, healthcare providers can develop tailored treatment plans. Genomic information provides valuable insights into disease risk, drug response, and prognosis, enabling personalised and targeted interventions.

In oncology, for example, genomic profiling of tumours helps identify specific genetic alterations driving the disease. This information guides treatment decisions, such as the selection of targeted therapies or immunotherapies. In other medical specialties, genomic information assists in diagnosing rare genetic disorders, determining optimal drug dosages based on individual metabolism, and identifying potential adverse drug reactions.

Challenges in Translating Genetic Insights into Health Improvements

While the journey from the genome to the phenome holds immense promise, it also presents challenges that need to be addressed. One significant challenge is the interpretation of genetic data. Analysing and understanding the vast amount of genetic information requires sophisticated bioinformatics tools and expertise. Ensuring the accuracy, reliability, and clinical relevance of genetic testing results is crucial for effective translation into clinical practice.

Another challenge lies in the ethical and privacy considerations associated with genetic testing. The potential for discrimination based on genetic information, the impact on insurance coverage, and the proper handling of sensitive data require careful attention and robust legal and ethical frameworks.

Furthermore, there is a need for improved education and awareness among healthcare providers and the general public. Healthcare professionals must be equipped with the knowledge and skills to interpret genetic information and effectively communicate with patients about the implications and limitations of genetic testing.

To overcome these challenges, collaboration between researchers, clinicians, genetic counsellors, policymakers, and patients is vital. Ongoing research, technological advancements, and the establishment of guidelines and standards can help ensure the responsible and effective translation of genetic insights into improved health outcomes.

The journey from the genome to the phenome represents the future of precision medicine. Genetic testing and the use of genomic information in clinical practice empower healthcare providers to deliver personalised and targeted treatments, resulting in improved health outcomes. However, addressing challenges related to interpretation, ethics, privacy, and education is crucial for realising the full potential of genetic insights in improving healthcare for individuals and populations.

Future Directions: Genomics, Phenomics, and Personalized Healthcare

The field of genomics has made remarkable strides in recent years, offering a deeper understanding of our genetic makeup and its impact on health and disease. The integration of genomics with phenomics—the study of how genes interact with the environment and influence observable traits—holds immense potential for personalised healthcare. As we look towards the future, several key directions are emerging, shaping the landscape of genomics, phenomics, and personalised healthcare.

1. Advancements in Genomic Technologies

Continued advancements in genomic technologies are expected to enhance our ability to analyse and interpret genetic data. Next-generation sequencing techniques, such as whole genome sequencing and whole exome sequencing, are becoming more affordable and accessible, enabling a more comprehensive assessment of an individual’s genetic profile. Additionally, advancements in high-throughput techniques and bioinformatics tools are facilitating large-scale analysis of genomic data, contributing to a deeper understanding of the complex interplay between genes and health outcomes.

2. Integration of Multi-Omics Data

The integration of genomics with other omics disciplines, such as transcriptomics, proteomics, metabolomics, and epigenomics, is anticipated to provide a more holistic view of human biology and disease. This multi-omics approach will enable researchers to uncover intricate molecular mechanisms underlying health and disease, offering novel insights into disease etiology, identification of biomarkers, and development of targeted therapies.

3. Population Genomics and Precision Public Health

Population genomics aims to characterise genetic variation and its distribution within populations. Large-scale genomic studies, such as genome-wide association studies (GWAS) and population-based sequencing initiatives, are generating extensive genomic data across diverse populations. By integrating population genomics with phenotypic and environmental data, precision public health strategies can be developed to identify population-specific health risks, tailor preventive measures, and improve public health interventions.

4. Artificial Intelligence and Machine Learning

Artificial intelligence (AI) and machine learning (ML) techniques are revolutionising the analysis and interpretation of genomic and phenomic data. These technologies can process vast amounts of data, identify patterns, and make predictions, facilitating the discovery of novel genetic associations, development of predictive models, and personalised treatment recommendations. AI and ML also hold promise in uncovering previously unrecognised genetic relationships and elucidating complex gene-environment interactions.

5. Ethical, Legal, and Social Implications (ELSI)

As genomics and personalised healthcare progress, it is essential to address the ethical, legal, and social implications that arise. Ensuring privacy and confidentiality of genomic data, promoting equity in access to genetic testing and personalised treatments, and addressing potential biases and discrimination are critical considerations. Collaborative efforts between researchers, policymakers, and ethicists are necessary to develop guidelines and frameworks that safeguard patient rights and promote responsible use of genomic information.

Conclusion: The Promising Intersection of Genomics and Phenomics

The convergence of genomics and phenomics holds tremendous promise for personalised healthcare. By understanding the complex interplay between genes, environment, and observable traits, healthcare can become more targeted, preventive, and effective. Genomic insights can aid in early disease detection, identification of individuals at higher risk, and tailoring treatment plans based on an individual’s genetic profile. Additionally, the integration of phenomics data allows for a more comprehensive understanding of an individual’s health, considering lifestyle, environmental factors, and social determinants.

However, realising the full potential of genomics and phenomics in personalised healthcare requires interdisciplinary collaborations, investment in research and infrastructure, and the development of robust data sharing platforms. By embracing these challenges and ethical considerations, we can leverage genomics and phenomics to usher in a new era of healthcare that is truly patient-centred, precise, and capable of improving health outcomes for individuals and populations alike.

Composed by: “Varsha, proficient as a Business Analyst, has an educational foundation in healthcare IT, acquired through a PGDHM from IIHMR Delhi. Her primary interest rests at the intersection of healthcare and technology, with a specific focus on harnessing cutting-edge tech solutions to revolutionize patient care and enhance healthcare systems. Her work areas comprise optimizing healthcare data flow and improving operational efficiency, driving enhanced patient care and system robustness.”

The post From genome to phenome: The impact of genetic insights on health outcomes appeared first on InnoHEALTH magazine.

HOW GENETIC TESTING CAN INNOVATE HEALTHCARE DELIVERY

InnoHEALTH Magazine — Tue, 02 May 2017 06:16:23 +0000

[vc_single_image image=”1277″ qode_css_animation=””]

How Genetic Testing can Innovate Healthcare Delivery

Dr. V.L Ramprasad holds a Master’s Degree and Ph.D. from BITS, Pilani. He has worked as Scientist (Molecular Genetics) at Vision Research Foundation, Sankara Nethralaya and was handling Affymetrix and Illumina technologies at Spinco Biotech. He also worked as Principal Scientist at SciGenom Labs. He has 17 peer-reviewed publications to his credit.

[vc_empty_space]

Though in a nascent stage, precision medicine is evolving at a fast pace. There are many labs set across the country and world which offer genetic testing at an affordable fee. Moving from a traditional medical model of treating pathologies to an individualized predictive and preventive model of personalized medicine promises to reduce the healthcare cost on an overburdened and overwhelmed system. The increasing number of catalogs of causative and risk genes will provide a foundation for Personalized Medicine and pharmacogenomics. The advent of NGS has helped in bringing down the cost of genome sequencing to less than $1000. However, there are many other new technologies on development that will make the sequencing even faster and more economical.

[vc_empty_space]

The current medical model focuses on the detection and treatment of pathologies. Treating disorders, especially on advanced states, is very expensive for patients and society in general. The Human Genome Project not only provided the essential reference map for the human genome but also stimulated the development of technology and analytic tools to process massive quantities of genomic data. Thus, accelerated the early detection of disorders and the identification of pharmacogenetic markers to customize treatments. Furthermore, the Human Genome Project has significantly contributed to the discovery of numerous genetic markers, several human disease-specific genomes, including cancers. Because of increased discovery rate of clinically relevant biomarkers, the relevant application of conventional molecular diagnostic methods like low- and/or medium-throughput sanger sequencing is restricted as they cannot screen such a huge number of genetic markers with a limited tumor/disease specific material. The advent of next-generation sequencing (NGS) technologies has not only reduced sequencing cost by orders of magnitude, but also significantly increased the throughput with just a few or single cell. One such new development in pre-natal genetic testing is “pre-implantation genetic screening”.

Pre-Implantation Genetic Screening

Chromosome segregation during female meiosis is particularly error prone in humans. These chromosomal abnormalities also called as Aneuploidy, worsen with advancing age. Many of recent studies have demonstrated that aneuploidy rates in the oocytes of women over 40 are over 75%, whereas approximately a quarter of oocytes from women in their early 30s are chromosomally abnormal.[1] A majority of human embryos produced from such oocytes using in vitro fertilization (IVF) techniques are aneuploid and has been shown that they fail to implant in the uterus, although a minority do succeed in forming a pregnancy only to later miscarry.[2] Hence, reliable identification of euploid (healthy) embryos is inevitable, but the main obstacle to testing human embryos for aneuploidy is the extremely limited amount of tissue available for analysis. Thus, most methods currently available for the genetic analysis of pre-implantation embryos may not be suitable and suffer from shortcomings which limit their clinical applicability. A few chromosome screening methods applicable to single cells biopsied from pre-implantation embryos are available, but the high cost of testing has restricted their usage.[3] New advancements in NGS technology provided an excellent alternative tool for the identification of chromosomal abnormalities using a few or single cell.

Next Generation Sequencing (NGS)

Next-generation sequencing popularly referred to as ‘high-throughput sequencing’. The advent of next-generation sequencing (NGS) technologies in the context of pre-natal genetic testing provides highly accurate, low-cost diagnosis of aneuploidy in cells from human pre-implantation embryos and is rapid enough to allow testing without embryo cryopreservation. Many reports indicated NGS improves IVF success rates. Thus, NGS becomes a reliable aneuploidy screening method and has the potential to revolutionize pre-implantation genetic screening (PGS).[4]

Furthermore, NGS becomes an integral part of precision medicine as it provides a viable alternative for characterizing genomic aberrations in tumors/other human disease for predictive and prognostic purposes with its massively parallel sequencing capability. This specific advantage of NGS technology enables testing of multiple genes/clinically relevant biomarkers per tumor as the standard-of-care, which may not be feasible with low- and medium-throughput traditional techniques such as Sanger sequencing, pyrosequencing, allele-specific polymerase chain reaction (PCR).[5,6,7]

The predominantly used NGS technologies are from:
• Illumina (HiSeq 2500/4000/X Ten etc.)
• Roche Applied Science/454 Life Sciences
• Life Technologies (Ion Torrent/Proton)
• Pacific Biosciences (Sequel)

The application of NGS technology in genetic testing is enormously increasing because it requires a single input of relatively low-quantity DNA or RNA for the screening of multiple markers, in contrast to traditional sequencing technologies, which need cumulatively larger quantities of input nucleic acid. NGS can provide simultaneous screening of a variety of genomic aberrations such as single-nucleotide variants (SNVs), multiple-nucleotide variants (MNVs), small and large insertions and deletions, and copy number variation (CNVs) of the genes. However, the benefits offered by these NGS technologies come with several challenges that must be adequately addressed before they can be transformed from research tools to routine clinical practices. Integrating NGS into a clinical diagnostic setting requires thorough validation with respect to consistent performance and accuracy, as per the stringent regulations and guidelines established by the regulatory agencies governing the clinical laboratories.[8]

Genetic Testing is Now More Accessible

More than a thousand genetic tests are available today and the number is still increasing. Genetic test panels give patients an insight into diseases which they may have inherited and give them an understanding of what preventive measures need to be taken. The results help understand the chances of a person liable to get inflicted by a genetic disorder and passing it on to someone else and vice versa. An expert in genetics is the best person to seek advice from, for those wanting to take a genetic test as such tests include risks and have their limitations as well. There are many labs set across the country and world which offer genetic testing at an affordable fee. Though many test labs have been established and it has been made more accessible, it continues to remain an expensive affair for the middle and lower middle sections of society in India.

Precision Medicine

Precision medicine or ‘specific treatment’ helps researchers and doctors to understand the exact treatment they need to offer to the patients. The advent of precision medicine is moving us closer to more precise, predictable and powerful health care that is customized for the individual patient. The approach of personalized therapy involves having a deep understanding of the unpredictability in a person’s genes, his/her environment and lifestyle. A complete bespoke treatment with appropriate decisions customized to a person’s medical condition. The therapies adopted range from imaging to molecular diagnostics and analytics/software and will be in accordance with the person’s genetic analysis. As mentioned previously, NGS becomes an integral part of precision medicine because of its high throughput and multiplexing capabilities which enables to analyze many clinically relevant markers across many samples.

The Future

Though it’s a nascent stage, precision medicine is evolving at a fast pace. Moving from a traditional medical model of treating pathologies to an individualized predictive and preventive model of personalized medicine promises to reduce the healthcare cost on an overburdened and overwhelmed system. The increasing number of catalogs of causative and risk genes will provide a foundation for Personalized Medicine and pharmacogenomics. The advent of NGS has helped in bringing down the cost of genome sequencing to less than $1000. However, there are many other new technologies on development that will make the sequencing even faster and more economical, such as Oxford Nanopore technologies (GridION™ System based on nanopore-based sensing). The future perspective of this advanced technology may reduce the cost of screening diseases specific gene panel to $100 within a time-frame of an hour. Research is proving that the therapies which are intended for one type of cancer could, in the future, be used to treat other types of cancers, on the premise of changes occurring in a person’s DNA. Discovery of mutations via sequencing and optional treatments are some of the findings through the process of sequencing and these may offer much hope towards better customized treatments for individuals.

[vc_empty_space]

Refernces:
[1] Fragouli E, Alfarawati S, Goodall NN, Sánchez-García JF, Colls P, Wells D. The cytogenetics of polar bodies: insights into female meiosis and the diagnosis of aneuploidy. Mol Hum Reprod, 2011;17:286–95.
[2] Scott RT, Ferry K, Su J, Tao X, Scott K, Treff NR. Comprehensive chromosome screening is highly predictive of the reproductive potential of human embryos: a prospective, blinded, nonselection study.Fertil Steril,2012;97:870-5.
[3] Fragouli E, Alfarawati S, Daphnis DD, Goodall NN, Mania A, Griffiths T, Gordon A, Wells D. Cytogenetic analysis of human blastocysts with the use of FISH, CGH and aCGH: scientific data and technical evaluation. Hum Reprod 2011;26:480–90.
[4] Hong KH, Taylor DM, Forman E, Tao X, Treff NR. Development of a novel next-gen sequencing (NGS) methodology for accurate characterization of genome-wide mitochondrial heteroplasmy in human embryos. Fertil Steril 2012;98:S58–9.
[5] Roychowdhury S, Chinnaiyan AM. Translating genomics for precision cancer medicine. Annu Rev Genomics Hum Genet. 2014; 15():395-415.
[6] Previati M, Manfrini M, Galasso M, Zerbinati C, Palatini J, Gasparini P, Volinia S. Next generation analysis of breast cancer genomes for precision medicine. Cancer Lett. 2013 Oct 1; 339(1):1-7.
[7] Roper N, Stensland KD, Hendricks R, Galsky MD. The landscape of precision cancer medicine clinical trials in the United States. Cancer Treat Rev. 2015 May; 41(5):385-90.
[8] Jennings L, Van Deerlin VM, Gulley ML, College of American Pathologists Molecular Pathology Resource Committee. Recommended principles and practices for validating clinical molecular pathology tests. Arch Pathol Lab Med. 2009 May; 133(5):743-55.

[vc_empty_space]

Want to write for InnoHEALTH? send us your article at magazine@innovatiocuris.com

[vc_separator type=”normal”]

Connect with InnovatioCuris on:
Facebook: https://www.facebook.com/InnovatioCuris
Twitter: https://twitter.com/innovatiocuris
Linkedin: https://www.linkedin.com/groups/7043791
Stay update about IC by visiting: www.innovatiocuris.com

Connect with InnoHEALTH 2017 on:
Facebook: https://www.facebook.com/innohealth2017
Twitter: https://twitter.com/innhealth2017
Linkedin: https://www.linkedin.com/groups/7043791
Stay update about the conference by visiting: www.innohealth.in

The post HOW GENETIC TESTING CAN INNOVATE HEALTHCARE DELIVERY appeared first on InnoHEALTH magazine.